CSPIA
FATE icon

Cary Street Partners Investment Advisory’s Fate Therapeutics FATE Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-85
Closed -$180 – 999
2023
Q3 		$180 Hold
85
– – ﹤0.01% 1833
2023
Q2 		$405 Buy
+85
New +$469 ﹤0.01% 1694

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Cary Street Partners Investment Advisory's FATE Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Fate Therapeutics (FATE) in Q4 2023, closing a stake of 85 shares — an estimated $180 sold.

Cary Street Partners Investment Advisory first reported a position in FATE in Q2 2023 and held it in 2 quarters. The position peaked at $405 in Q2 2023. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Fate Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 85 Fate Therapeutics shares in Q4 2023, an estimated $180.
  • Cary Street Partners Investment Advisory first reported a position in Fate Therapeutics in Q2 2023 and held it in 2 quarters.
  • Cary Street Partners Investment Advisory's Fate Therapeutics position peaked at $405 in Q2 2023.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.